• 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

6609 Share Price Performance

HK$0
-29.00 (-100.00%)
HK$0
-29.00 (-100.00%)
Price HK$0

6609 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with moderate growth potential.

1 Risk
3 Rewards

Shanghai HeartCare Medical Technology Corporation Limited Key Details

CN¥334.9m

Revenue

CN¥117.0m

Cost of Revenue

CN¥218.0m

Gross Profit

CN¥175.5m

Other Expenses

CN¥42.4m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
1.12
65.08%
12.67%
0%
View Full Analysis

About 6609

Founded
2016
Employees
327
CEO
Guohui Wang
WebsiteView website
www.heartcare.com.cn

Shanghai HeartCare Medical Technology Corporation Limited engages in the research and development, manufacture, and sale of neuro-interventional medical devices in Mainland China and internationally. It offers ischemic stroke thrombectomy devices, such as Captor Thrombectomy Stent, a thrombectomy stent retriever; aspiration catheter and pump; intracranial stenosis treatment devices, including intracranial drug-eluting balloon stent, embolization protection system, carotid artery stent, and intracranial balloon dilatation catheter and carotid artery balloon dilatation catheter; hemorrhagic stroke treatment devices, including vascular reconstruction device and flow diverter device; and ischemic stroke prevention devices comprising LAA occlude. The company also provides vascular access devices consisting of distal access catheter, microcatheter, balloon guiding catheter, vascular closure device, support catheter, neuro-interventional microcatheter, neuro-interventional micro guidewire, microcatheter for coiling, microcatheter for flow diverter device, and navigation catheter. Its products are used for acute ischemic stroke and neurovascular stenosis treatment, hemorrhagic stroke treatment, ischemic stroke prevention, and interventional access. The company was incorporated in 2016 and is headquartered in Shanghai, the People’s Republic of China.

Recent 6609 News & Updates

Recent updates

No updates